WEBULL
WebtradeDownload

Genpact (G) Stock Price Drops As AI Growth Challenges Legacy Slowdown

Simply Wall St · 1d ago

Genpact stock just absorbed a 5% hit in the first full trading session after earnings, yet the quarter itself looked far more constructive than that price move suggests. Investors came in after a strong 30 day run and then sold on the headline, even as Genpact’s Advanced Technology Solutions revenue grew to about US$363m and helped lift adjusted diluted earnings per share to US$1.00.

The key development is a business services company placing greater emphasis on higher margin, data and artificial intelligence focused work while the market briefly concentrates on the red ink in today’s price chart.

Is Genpact’s 9.9x P/E and the large gap to a modeled US$108.83 fair value a genuine mispricing, or a warning sign about slower forecast growth? Compare Genpact’s earnings power against that valuation gap in the valuation analysis for Genpact

Q2 2026 Earnings Summary

  • Revenue (Q2 2026 vs. Q2 2025): US$1,343.4m vs. US$1,254.4m (up 7.1%).
  • Net Income (Excl. Extra Items, Q2 2026 vs. Q2 2025): US$145.7m vs. US$132.7m (up 9.8%).
  • Basic EPS (Earnings Per Share, Q2 2026 vs. Q2 2025): US$0.86 vs. US$0.76 (up 13.5%).
  • Gross Margin (Q2 2026 vs. Q2 2025): 36.5% vs. 35.9% (expansion of 60 bps).

Prefer clear charts over another wall of numbers and footnotes? You can see Genpact’s full financial picture with an easy visual read on valuation in our company report for Genpact.

NYSE:G Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
NYSE:G Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

Genpact’s AI Mix Shift Starts To Show Its Work

The bullish view on Genpact is that turning traditional outsourcing into AI led, agentic operations will lift growth quality, margins and earnings resilience. Q2 gives several concrete milestones that move this from story to execution. Advanced Technology Solutions reached about US$363m and grew in the mid 20s %, and now accounts for roughly 27% of revenue and about 40% of bookings. That supports the idea that AI centric work is gaining commercial traction rather than sitting in pilots.

Non FTE revenue crossing 50% of total, with ATS more than 70% annuitized and more than 70% on non FTE models, directly backs the claim of a more recurring, less labor linked business mix. Gross margin expanding to 36.5% for the 13th consecutive quarter and adjusted EPS rising 13.6% to US$1.00 are in line with the thesis that this mix shift can support steadily higher profitability.

Compare Genpact’s margin progress and the rising share of AI centric revenue with how institutional analysts are framing the stock after the post earnings price drop. See the consensus price target analysis for Genpact.

Genpact Bear Case: Execution Friction Shows Through The Mix

The bearish view is that Genpact’s AI and Agentic Operations story encounters real world friction, with slow client adoption, vendor consolidation, and delivery risk capping growth and margins. Q2 does not fully clear that hurdle. ATS grew strongly and lifted gross margin, yet Core Business Services revenue of US$980m rose only 1.9%. Management now expects CBS to be flat to slightly down in Q3 once transition headwinds hit. That aligns with concerns that legacy work is shrinking faster than new AI programs ramp.

Bears also worry that outcome based contracts and heavy AI talent spend squeeze earnings. Guidance still points to only modest adjusted operating margin expansion to about 17.7% for 2026, despite ATS representing roughly 27% of revenue and more than 70% annuitized. The largest ever bookings and a growing agentic pipeline help, but the results indicate that the margin step up many bulls anticipated has not materialized yet.

With Genpact now trading down 5.2% after earnings while bookings set records and margins edge higher, it is worth asking whether the balance sheet can comfortably support this AI heavy pivot. Check the full solvency, liquidity and cash coverage profile in our financial health analysis of Genpact stock.

Stay Ahead With Simply Wall St

If the mix of Genpact’s AI led growth and short term price pressure has your attention, register for free with Simply Wall St and add it to a Watchlist to track share price moves against fair value and watch how the thesis develops. Once you own Genpact or other stocks, use the Portfolio Command Center to cut through market noise and focus on the key financial and fundamental updates that matter most. For longer term conviction, turn to the Community to see how other investors are thinking about opportunities and risks across similar stories. By surfacing hidden catalysts and potential red flags early, you can stay in front of the market instead of reacting to it late.

Seeking Fresh Alternatives Beyond Genpact?

Fresh stock ideas often see momentum build quietly before a breakout, and early entries can move significantly once the crowd catches on. Scan these under the radar opportunities while it matters and consider them while they remain less widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.